PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,200 shares, a growth of 33.3% from the February 13th total of 6,900 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 29,000 shares, the days-to-cover ratio is presently 0.3 days.
PolyPid Stock Performance
PYPD stock traded up $0.01 during trading on Friday, reaching $2.95. 9,909 shares of the stock were exchanged, compared to its average volume of 13,253. PolyPid has a twelve month low of $2.37 and a twelve month high of $5.50. The company has a market capitalization of $30.10 million, a P/E ratio of -0.59 and a beta of 1.27. The stock has a 50 day simple moving average of $3.02 and a 200-day simple moving average of $3.23. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08.
PolyPid (NASDAQ:PYPD – Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). As a group, sell-side analysts anticipate that PolyPid will post -1.79 earnings per share for the current year.
Analysts Set New Price Targets
View Our Latest Stock Report on PolyPid
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of PYPD. Rosalind Advisors Inc. raised its stake in shares of PolyPid by 50.6% in the fourth quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock valued at $3,108,000 after acquiring an additional 343,353 shares during the last quarter. AIGH Capital Management LLC raised its stake in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares during the last quarter. Stonepine Capital Management LLC bought a new position in PolyPid in the 3rd quarter worth approximately $476,000. Finally, J. Goldman & Co LP bought a new position in PolyPid in the 4th quarter worth approximately $391,000. Institutional investors own 26.47% of the company’s stock.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Stories
- Five stocks we like better than PolyPid
- Compound Interest and Why It Matters When Investing
- How to Build the Ultimate Everything ETF Portfolio
- What is a buyback in stocks? A comprehensive guide for investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.